Evidence map›Paper›PMID 37646658›Full record

ArticleHaematologica2024

The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.

Lindsay Hammons, Aniko Szabo, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Binod Dhakal, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Ravi Narra, Divaya Bhutani and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 6 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 6 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Lindsay HammonsDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Aniko SzaboDivision of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI.
Abhishek JanardanMedical College of Wisconsin Medical School, Milwaukee, WI.
Vineel BhatlapenumarthiDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Evanka AnnyapuMedical College of Wisconsin Medical School, Milwaukee, WI.
Binod DhakalDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Samer Al HadidiMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR.
Sabarinath Venniyil RadhakrishnanDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Ravi NarraDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Divaya BhutaniMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, NY.
Sharmilan ThanendrarajanMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR.
Siegfried JanzDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Maurizio ZangariMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR.
Suzanne LentzschMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, NY.
Frits Van RheeMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR.
Juan Carlos Rico CrescencioInternal Medicine, Division of Infection Disease, University of Arkansas for Medical Science, Little Rock, AR.
Anita D'SouzaDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Rajshekhar ChakrabortyMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, NY.
Meera MohanDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Carolina SchinkeMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR. CDSchinke@uams.edu.
Medical College of Wisconsin · USUniversity of Arkansas for Medical Sciences · USAmyloidosis Foundation · USUniversity of Arkansas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a paucity of granular data on infection risk with B-cell maturation antigen (BMCA) and GPRC5D bispecific antibodies (bsAb) in relapsed/refractory multiple myeloma (RRMM). The aim of our multi-institutional study was to characterize the incidence, etiologies, and risk factors of infections from the start of therapy to the last follow-up or 90 days after study exit. A total of 66 patients received BCMA bsAb monotherapy, 15 GPRC5D bsAb monotherapy, and 15 GPRC5D bsAb combination therapy with daratumumab and/or pomalidomide. While the infection rate per 100 days was 0.57 for BCMA bsAb, it was 0.62 for GPRC5D bsAb combination and 0.13 for GPRC5D bsAb monotherapy; P=0.05. The proportion of infections that were grade ≥3 was higher in the BCMA bsAb group compared to the GPRC5D groups (58% vs. 36%; P=0.04). Grade 5 events were observed in 8% (n=8) of the patients, all treated with BCMA bsAb. The 9 month cumulative incidence of any grade of infection was similar in the BCMA and GPRC5D-combination groups (57% and 62%) and significantly higher than in the GPRC5D-mono group (16%); P=0.012. The cumulative incidence of grade ≥3 infections was highest in the BCMA group reaching 54% at 18 months; P=0.06. Multivariate analysis showed that BCMA bsAb therapy or GPRC5D combination therapy, history of previous infections, baseline lymphopenia, and baseline hypogammaglobulinemia were significantly associated with a higher risk of grade ≥3 infections. Our results indicate that BCMA bsAb and GPRC5D-combination therapies in RRMM are associated with higher cumulative incidence of infection and grade ≥3 infection compared to GPRC5D bsAb mono.

Indexed as

Antibodies, BispecificMultiple MyelomaNeoplasms, Plasma CellB-Cell Maturation AntigenCombined Modality TherapyHumansReceptors, G-Protein-CoupledAntibodies, BispecificB-Cell Maturation AntigenGPRC5D protein, humanReceptors, G-Protein-Coupled

Identifiers

PMID37646658
PMCPMC10905074
OpenAlexW4386272219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.